Morshedzadeh N(1), Shahrokh S(2), Chaleshi V(2), Karimi S(3), Mirmiran P(3), Zali MR(2). Author information:
(1)Department of Nutrition, School of Public Health, Kerman University of
Medical Sciences, Kerman, Iran.
(2)Gastroenterology and Liver Diseases Research Center, Research Institute for
Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical
Sciences, Tehran, Iran.
(3)Nutrition and Endocrine Research Center, Research Institute for Endocrine
Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
AIMS: Inflammatory bowel disease, a chronic inflammatory disorder of the intestinal mucosa, is a clinical presentation of Crohn's disease and ulcerative colitis (UC). This study investigated the effect of grounded flaxseed (GF) and flaxseed oil (FO) on clinical biomarkers, quality of life and diseases activity in patients with UC. This research was conducted among 90 patients with UC for 12 weeks using an open-labelled randomised controlled trial design. METHODS: The participants were randomly assigned into two intervention groups supplemented with GF (30 gr/day) and FO (10 gr/day) as well as a control group. The participants' data were collected prior to and 12 weeks after the intervention. The one-way analysis of variance was run to compare variables. RESULTS: A total of 75 patients completed the study. After the intervention, hs-CRP (P < .001) and Mayo score (P < .001) were reduced significantly, but quality of life was increased significantly (P < .001) in the GF and FO groups compared with the control. A significant increase was observed in IL-10 concentration in the FO group, but no significant change was found in serum levels of IL-10 in the control group. Moreover, the decrease in Mayo score was greater in patients at more severe stages of the disease (P < .05). No difference was observed between the intervention groups and control group in mRNA expression level of TLR4 at the 12th week. CONCLUSION: In conclusion, grounded flaxseed and FO attenuated systemic inflammation and improved disease severity in UC patients.
Having over 250 Research scholars worldwide and more than 400 articles online with open access.